HULL HANS (Chief Business Officer) sold 4.3% of their position (9.04K shares) of PLIANT THERAPEUTICS, INC. on the open market
Open‑market sale worth $239.6K — a minor trim. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 4/3/2023ACC: 0001209191-23-022369
Officer· Chief Business Officer
Since Jun 2020
-9.04K
Net shares
Net seller
$239.6K
Total sold
1
Open market trades
0B · 1S
1
Total transactions
9.04K disposed
Non-Derivative Transactions1
Common Stock
Direct
Shares
−9.04K
Price / share
$26.52
Trade value
$239.64K
% of position
4.3%
3/30/2023
211K→201.96K
Total
Net shares
−9.04K
Net value
-$239.64K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 3/30/2023 | S · Sale | −9.04K | $26.52 | $239.64K | 4.3% | 211K | 201.96K |
| Total | −9.04K | -$239.64K | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)3
Common Stock
IndirectShares owned13.98K
Common Stock
IndirectShares owned3.82K
Common Stock
IndirectShares owned13.98K
Total
31.79K indirect31.79K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 13.98K | Indirect |
| Common Stock | 3.82K | Indirect |
| Common Stock | 13.98K | Indirect |
| Total | 31.79K | 31.79K indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported